Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION
ROCHE DIAGNOSTICS CORPORATION,
Plaintiff,
vs.
APEX BIOTECHNOLOGY CORP, et. al.,
Defendants.
)))
) 1:04-cv-0358- LJM/VSS
)))
ENTRY FOR NOVEMBER 15, 2005
MAGISTRATE JUDGE V. SUE SHIELDS
This cause is set for a settlement conference on November 22, 2005 at 9:30 A.M. in
Room 256, United States Courthouse, 46 E. Ohio Street, Indianapolis, Indiana, before the
Honorable V. Sue Shields.
Unless excused by order of the court, clients or client representatives with complete
authority to negotiate and consummate a settlement shall attend the settlement conference along
with their counsel. This requires the presence of each party, or the authorized representative of
each corporate, governmental, or other organizational entity. For a defendant, such
representative must have final settlement authority to commit the organization to pay, in the
representatives own discretion, a settlement amount up to the plaintiffs prayer, or up to the
plaintiffs last demand, whichever is lower. For a plaintiff, such representative must have final
authority, in the representatives own discretion, to authorize dismissal of the case with
prejudice, or to accept a settlement in the amount of the defendants last offer. Any insurance
company that is a part, or is contractually required to defend or indemnify any party, in whole or
in part, must have a fully authorized settlement representative present at the conference. Such
representative must have final settlement authority to commit the company to pay, in the
Case 1:04-cv-00358-LJM-VSS Document 312 Filed 11/15/2005 Page 1 of 3

representatives own discretion, an amount within the policy limits, or up to the plaintiffs last
demand, whichever is lower. If trial counsel has been fully authorized to commit the client to
pay or to accept in settlement the amount last proposed by the opponent, in counsels sole
discretion, the client, client representative, or insurance company, as applicable, need not attend.
Counsel are responsible for timely advising any involved non-party insurance company of the
requirements of this order. The purpose of this requirement is to have in attendance a
representative who has both the authority to exercise his or her own discretion, and the
realistic freedom to exercise such discretion without negative consequences, in order to
settle the case during the settlement conference without consulting someone else who is not
present.
Each party shall submit (not file) a confidential settlement statement directly to the
magistrate judge no later than two business days prior to the conference, setting forth the
relevant positions of the party concerning factual issues, issues of law, damages, and the
settlement negotiation history of the case, including a recitation of any specific demands and
offers that have been conveyed.
Copies to:

Case 1:04-cv-00358-LJM-VSS Document 312 Filed 11/15/2005 Page 2 of 3

List of names.....

Back in this morning @ 2.80

moneyman
You beat me to it well done, and you baz.

20p by close on that good news then

Wouldn't that be nice - but somehow - I doubt it.!!!

But I will still cross my fingers

Baza

katcenka
Here's hoping.

A settlement conference is a pretrial meeting between the parties and a judge to work out an agreement instead of going to trial. This encourages the parties to find a solution each can agree to. It is less expensive than the attorney fees and court fees for a formal hearing or trial, and it provides the parties with some control over the outcome. A settlement conference is different from mediation in that the judge may offer an opinion about the likely outcome of the case if it were to go to trial.

So it looks like we are going to have a settlement sooner than we thought.

yes but how much is the settlement going to be, I heard Apex is paying Roche rather than the other way round, whats that about

A D V F N is down, power cut maybe

Medisys are in a good position, it may be that Roche wants a conclusion to this case instead of it dragging on and incurring more and more costs.

New stuff on the cc, on the cc Page.
22/11/2005
http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

New stuff on the cc, on the cc Page.
22/11/2005
http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

finals on Dec 9th-maybe we'll get some good news.

mp
Don't hold your breath its the cc we want to see the back of.

We are on the move results out tomorrow may be interesting.

driver how long are you holding on this one for a result--1year or longer?? I'm happy to wait I just wondered when the orders will start producing a lift in sp. tomorrow I hope.

All

posted this on a different thread...

MDY

Activity the past 48hrs - looks like a possible yoyo on the way again...

DYOR - obviously

Next few days could well be interesting.

666

mp
Don't the answer to that I can see a future recovery of 10p to 20p but I don't know the time scale, tomorrow could go either way then we have the cc to sort out next Jan its hold on to your hat time.

cheers driver-this is another like pcm needs patience. MP

Results out

CURRENT TRADING AND PROSPECTS
The current financial year is at an early stage, but to date trading has been in
line with expectations. Growth is expected to come primarily from the biosensor
based products, specifically through the alliance with Menarini and from the
introduction of the Assure Pro system into the LTC market. In addition the cost
savings realised in the latter part of 2005 will help to improve the financial
performance of the Group in the current year.

The Roche Case
The Directors remain of the opinion that Hypoguard shall be successful in
defending against the remaining claim. To date, all costs associated with
Hypoguard's defence of the claims have been paid by Apex Biotechnology Corp, the
manufacturer of the Assure products, under the terms of an indemnity provided by
Apex to Hypoguard

http://moneyam.uk-wire.com/cgi-bin/articles/200512090700343972V.html

Time to abandon I think - maybe too late